Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,734

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arpita Dutt headshot

Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises

by Arpita Dutt

Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.

    Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe

    by Zacks Equity Research

    Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.

      Merck's CETP Inhibitor Reduces CV Risk in Phase III Study

      by Zacks Equity Research

      Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.

        Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval

        by Zacks Equity Research

        Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.

          Allergan Continues to Focus on Acquisitions and Branded Unit

          by Zacks Equity Research

          We issued an updated research report on Allergan plc (AGN) on Jun 23.

            Arpita Dutt headshot

            Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

            by Arpita Dutt

            All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

              Novartis Announces Positive Results for Cardiovascular Drug

              by Zacks Equity Research

              Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.

                Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                by Zacks Equity Research

                Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                  Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study

                  by Zacks Equity Research

                  Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.

                    Novartis (NVS) Biosimilar of MabThera Approved in the EU

                    by Zacks Equity Research

                    Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon.

                      Celgene Presents Interim Results from Cancer Drug Study

                      by Zacks Equity Research

                      Celgene Corporation (CELG) announced encouraging results from an interim analysis of a phase IIIb study, MAGNIFY, on Revlimid.

                        Does Roche Holding (RHHBY) Look to be a Great Value Pick?

                        by Zacks Equity Research

                        Roche Holding is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                          J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

                          by Zacks Equity Research

                          Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

                            Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year

                            by Zacks Equity Research

                            Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.

                              Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval

                              by Zacks Equity Research

                              Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.

                                Why is Alnylam's (ALNY) Stock Close to 100% this Year?

                                by Zacks Equity Research

                                Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.

                                  Epizyme Provides Positive Interim Data on EZH2 Inhibitor

                                  by Zacks Equity Research

                                  Epizyme, Inc. (EPZM) announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat as a monotherapy in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma

                                    Exelixis Initiates Cabozantinib-Tecentriq Combination Trial

                                    by Zacks Equity Research

                                    Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.

                                      Why is Kite Pharma (KITE) Stock Up Close to 100% this Year?

                                      by Zacks Equity Research

                                      Shares of Kite Pharma, Inc. (KITE) were up around 5.6% on Thursday.

                                        Allergan to Buy Keller Funnel, Boost Plastic Surgery Unit

                                        by Zacks Equity Research

                                        Allergan plc (AGN) announced a deal to acquire privately held medical device company Keller Medical, Inc, which makes Keller Funnel, for an undisclosed amount.

                                          Roche Announces Data on Perjeta, Alecensa and Tecentriq

                                          by Zacks Equity Research

                                          Roche announced a series of data on various cancer drugs like Perjeta, Alecensa and Tecentriq at ASCO.

                                            Arpita Dutt headshot

                                            Key FDA Events to Watch Out for in Jun 2017

                                            by Arpita Dutt

                                            Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

                                              Novartis Reports Positive Data on Breast Cancer Drug Kisqali

                                              by Zacks Equity Research

                                              Novartis AG (NVS) announced positive data from the phase III study, MONALEESA-2 on breast cancer drug Kisqali.

                                                Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B

                                                by Zacks Equity Research

                                                Novo Nordisk (NVO) announced that the FDA has approved the Biologics License Application (BLA) for Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.

                                                  Novartis Biosimilar Pipeline, 2018 Growth Plans on Track

                                                  by Zacks Equity Research

                                                  Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie's (ABBV) Humira (adalimumab) and Johnson & Johnson's (JNJ) Remicade (infliximab) for review.